Transcode Therapeutics Stock Performance
| RNAZ Stock | USD 8.58 0.40 4.45% |
The entity has a beta of 0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Transcode Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Transcode Therapeutics is expected to be smaller as well. Transcode Therapeutics right now has a risk of 6.15%. Please validate Transcode Therapeutics maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Transcode Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Over the last 90 days Transcode Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Transcode Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 13.81 | Five Day Return (8.53) | Year To Date Return 34.73 | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:28 | Last Split Date 2025-05-15 |
1 | Goldman Sachs Group Inc Significantly Reduces Holdings in TransCode Therapeutics Inc - GuruFocus | 11/14/2025 |
2 | TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer | 11/17/2025 |
3 | Acquisition by Robert Dudley of 135000 shares of Transcode Therapeutics subject to Rule 16b-3 | 11/28/2025 |
4 | TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCo... | 12/11/2025 |
5 | Insider Trading | 12/19/2025 |
6 | TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors | 12/22/2025 |
7 | Price Dynamics and Execution-Aware Positioning - Stock Traders Daily | 01/07/2026 |
8 | Market Catalysts Is TransCode Therapeutics Inc a speculative investment - Quarterly Portfolio Report Fast Gain Swing Alerts - baoquankhu1.vn | 01/21/2026 |
| Begin Period Cash Flow | 2.8 M | |
| Total Cashflows From Investing Activities | -21.8 K |
Transcode | Build AI portfolio with Transcode Stock |
Transcode Therapeutics Relative Risk vs. Return Landscape
If you would invest 940.00 in Transcode Therapeutics on November 8, 2025 and sell it today you would lose (82.00) from holding Transcode Therapeutics or give up 8.72% of portfolio value over 90 days. Transcode Therapeutics is currently generating 0.0204% in daily expected returns and assumes 6.154% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Transcode, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Transcode Therapeutics Target Price Odds to finish over Current Price
The tendency of Transcode Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.58 | 90 days | 8.58 | about 60.66 |
Based on a normal probability distribution, the odds of Transcode Therapeutics to move above the current price in 90 days from now is about 60.66 (This Transcode Therapeutics probability density function shows the probability of Transcode Stock to fall within a particular range of prices over 90 days) .
Transcode Therapeutics Price Density |
| Price |
Predictive Modules for Transcode Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Transcode Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Transcode Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Transcode Therapeutics is not an exception. The market had few large corrections towards the Transcode Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Transcode Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Transcode Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 1.22 | |
Ir | Information ratio | -0.06 |
Transcode Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Transcode Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Transcode Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Transcode Therapeutics had very high historical volatility over the last 90 days | |
| Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (13.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Market Catalysts Is TransCode Therapeutics Inc a speculative investment - Quarterly Portfolio Report Fast Gain Swing Alerts - baoquankhu1.vn |
Transcode Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Transcode Stock often depends not only on the future outlook of the current and potential Transcode Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Transcode Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 356.1 K | |
| Cash And Short Term Investments | 5.8 M |
Transcode Therapeutics Fundamentals Growth
Transcode Stock prices reflect investors' perceptions of the future prospects and financial health of Transcode Therapeutics, and Transcode Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transcode Stock performance.
| Return On Equity | -17.63 | ||||
| Return On Asset | -2.33 | ||||
| Current Valuation | 2.76 M | ||||
| Shares Outstanding | 916.97 K | ||||
| Price To Book | 5.77 X | ||||
| EBITDA | (16.19 M) | ||||
| Net Income | (16.75 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 38.29 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 1.71 X | ||||
| Cash Flow From Operations | (13.34 M) | ||||
| Earnings Per Share | (225.98) X | ||||
| Market Capitalization | 7.87 M | ||||
| Total Asset | 7.29 M | ||||
| Retained Earnings | (63.2 M) | ||||
| Working Capital | 4.32 M | ||||
About Transcode Therapeutics Performance
Evaluating Transcode Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Transcode Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Transcode Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.64) | (2.77) | |
| Return On Capital Employed | (3.98) | (4.18) | |
| Return On Assets | (2.64) | (2.77) | |
| Return On Equity | 9.54 | 10.02 |
Things to note about Transcode Therapeutics performance evaluation
Checking the ongoing alerts about Transcode Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Transcode Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Transcode Therapeutics had very high historical volatility over the last 90 days | |
| Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (13.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Market Catalysts Is TransCode Therapeutics Inc a speculative investment - Quarterly Portfolio Report Fast Gain Swing Alerts - baoquankhu1.vn |
- Analyzing Transcode Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transcode Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Transcode Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Transcode Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transcode Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Transcode Therapeutics' stock. These opinions can provide insight into Transcode Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.